| pubmed-article:15190528 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C2349001 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C0681850 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C1706203 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C2697811 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C1882085 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C0264716 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C1579762 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C1550501 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C0009491 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C2699007 | lld:lifeskim |
| pubmed-article:15190528 | lifeskim:mentions | umls-concept:C0969523 | lld:lifeskim |
| pubmed-article:15190528 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15190528 | pubmed:dateCreated | 2004-6-10 | lld:pubmed |
| pubmed-article:15190528 | pubmed:abstractText | Chronic heart failure (CHF) can be caused either by a predominant abnormality in systolic function (systolic heart failure) or a predominant abnormality in diastolic function (diastolic heart failure). Randomized clinical trials have identified a number of pharmaceutical agents that can reduce morbidity and mortality in patients with systolic heart failure. Despite significant therapeutic advances, systolic heart failure continues to result in high rates of morbidity and mortality. In contrast to systolic heart failure, no randomized clinical trials have been performed in patients with diastolic heart failure. Common to the mechanisms causing both systolic and diastolic heart failure are abnormalities in calcium homeostasis. Mitsubishi Pharma Corporation has developed a compound (MCC-135, INN; caldaret) whose mechanism of action is proposed to be modulation of calcium homeostasis at the sarcoplasmic reticulum and cellular membrane. The purpose of this study was to test the safety, tolerability, and efficacy of MCC-135 in patients with mild to moderate heart failure. | lld:pubmed |
| pubmed-article:15190528 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15190528 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15190528 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15190528 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15190528 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15190528 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15190528 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15190528 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15190528 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15190528 | pubmed:issn | 1071-9164 | lld:pubmed |
| pubmed-article:15190528 | pubmed:author | pubmed-author:TavazziLuigiL | lld:pubmed |
| pubmed-article:15190528 | pubmed:author | pubmed-author:LittleWilliam... | lld:pubmed |
| pubmed-article:15190528 | pubmed:author | pubmed-author:FrancisGaryG | lld:pubmed |
| pubmed-article:15190528 | pubmed:author | pubmed-author:DaviesMartinM | lld:pubmed |
| pubmed-article:15190528 | pubmed:author | pubmed-author:ClelandJohnJ | lld:pubmed |
| pubmed-article:15190528 | pubmed:author | pubmed-author:ZileMichaelM | lld:pubmed |
| pubmed-article:15190528 | pubmed:author | pubmed-author:GaaschWilliam... | lld:pubmed |
| pubmed-article:15190528 | pubmed:author | pubmed-author:MCC-135 GO1... | lld:pubmed |
| pubmed-article:15190528 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15190528 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:15190528 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15190528 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15190528 | pubmed:pagination | 193-9 | lld:pubmed |
| pubmed-article:15190528 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:meshHeading | pubmed-meshheading:15190528... | lld:pubmed |
| pubmed-article:15190528 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15190528 | pubmed:articleTitle | A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. | lld:pubmed |
| pubmed-article:15190528 | pubmed:affiliation | Cardiology Division, Department of Medicine, Gazes Cardiac Research Institute, Medical University of South Carolina, and the Ralph H. Johnson, Department of Veterans Affairs Medical Center, Charleston, 29425, USA. | lld:pubmed |
| pubmed-article:15190528 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15190528 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15190528 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15190528 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15190528 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:15190528 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15190528 | lld:pubmed |
